Publication | Closed Access

Evaluation of risk factors predictive of nausea and vomiting with current standard-of-care antiemetic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy

Drug SafetyCisplatin-based ChemotherapyPhase Iii TrialsMedicineSymptomatic TreatmentPatient SafetyClinical TrialsOutcomes ResearchPharmacotherapySide EffectOncologyRadiation OncologyRisk FactorsAdverse Drug ReactionHealth Sciences